The U.S. Environmental Protection Agency (EPA) issued a final rule on June 9, 2025, that extends the reporting deadlines for ...

The study is expected to start in H2 2023, chief business officer David Chung told Clinical Trials Arena. PLB-1004 is a novel mono-anilino-pyrimidine small molecule that inhibits EGFR and targets exon ...

PLB1004, a novel mono-anilino-pyrimidine small molecule inhibitor of EGFR, potently and irreversibly targets exon 20 insertion. The molecule also potently targets classical EGFR mutations ExDel19 ...

The development of many useful protective groups has been reported based on the functionality of the anilino group. Herein, we discuss our study of various protective groups and the processes we used ...

The companies — Corporativo y Enlace Ram, Corporativo Escomexa, and Grupo Pochteca — allegedly imported key substances like 4-Anilino-N-phenethyl-4-piperidine, propionyl chloride, and aniline from ...

It’s 2-anilino-5-([4-methylpentan-2-yl]amino)cyclohexa-2,5-diene-1,4-dione, or 6PPD-quinone for short. Never heard of it? You’re not alone. You can’t buy it anywhere. No one manufactures it.

It’s 2-anilino-5-([4-methylpentan-2-yl]amino)cyclohexa-2,5-diene-1,4-dione, or 6PPD-quinone for short. Never heard of it? You’re not alone. You can’t buy it anywhere. No one manufactures it.

Several 2-anilino-3-aroylquinolines were designed, synthesized, and screened for their cytotoxic activity against five human cancer cell lines: HeLa, DU-145, A549, MDA-MB-231, and MCF-7. Their IC50 ...